Dexamethasone – Medxy AI

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

By MedXY 08/26/2026

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.

Infectious Diseases Neurology news

Adjunct Dexamethasone in Herpes Simplex Encephalitis: Safe but Fails to Improve Long-Term Verbal Memory in the DexEnceph Trial

By MedXY 01/29/2026

The Phase 3 DexEnceph trial found that adjunct dexamethasone is safe in adults with HSV encephalitis but does not significantly improve verbal memory scores at 26 weeks compared to aciclovir monotherapy, suggesting a need for earlier or more targeted immunomodulation.

Hematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Clinical Updates Hematology-Oncology news Specialties

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

By MedXY 08/30/2025

The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.

Clinical Updates Hematology-Oncology news Specialties

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY 08/07/2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxicity.

Family Medicine & Nutrition Medical News news Specialties

Dexamethasone: Essential Precautions and Key Drug Interactions to Know

By MedXY 08/03/2025

Dexamethasone is a powerful corticosteroid that requires careful use due to potential harmful drug interactions and side effects. This article highlights crucial precautions and compatibility issues for safe administration.